文献速递脊柱关节炎

托法替布治疗银屑病关节炎的疼痛改善时间及基线疼痛严重程度的影响

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib.
PubMed 文献 · RMD Open · 2021-01-01

该事后分析基于两项试验,评估银屑病关节炎患者接受托法替布5 mg每日两次、安慰剂转托法替布或阿达木单抗后疼痛改善时间及基线疼痛严重程度对疼痛反应的影响。结果显示托法替布和阿达木单抗比安慰剂疼痛改善更快,且托法替布组基线疼痛越高疼痛改善越快。

要点

  • 托法替布组初始疼痛改善≥30%中位55天,安慰剂转托法替布组106天。
  • 托法替布组持续疼痛改善≥50%中位171天,安慰剂转托法替布组未估计。
  • 托法替布组基线疼痛越高,预测疼痛改善时间越短。

核心结论

  • 托法替布和阿达木单抗比安慰剂使更多患者疼痛改善且更迅速。
  • 接受托法替布的患者中,基线疼痛越高与疼痛改善越快相关。

研究设计与样本

  • 两项试验(NCT01877668;NCT01882439)的事后分析。
  • 患者接受托法替布5 mg每日两次、安慰剂第3个月转托法替布5 mg每日两次或阿达木单抗(仅NCT01877668)。

主要发现

  • 第3个月时,托法替布/阿达木单抗组比安慰剂组更多患者疼痛改善。
  • 托法替布组初始疼痛改善≥30%中位55天(95%CI 29-57),持续≥30%中位60天(95%CI 57-85)。
  • 托法替布组初始疼痛改善≥50%中位85天(95%CI 57-92),持续≥50%中位171天(95%CI 90-未估计)。
  • 安慰剂转托法替布组初始≥30%中位106天(95%CI 64-115),持续≥30%中位126天(95%CI 113-173)。
  • 安慰剂转托法替布组初始≥50%中位169天(95%CI 120-189),持续≥50%未估计(95%CI 247-未估计)。

关键数值与推荐

  • 疼痛改善定义为视觉模拟量表疼痛评分较基线下降≥30%或≥50%。
  • 中位时间通过Kaplan-Meier法估计,参数模型用于分析基线疼痛严重程度与疼痛反应时间的关系。

临床怎么用

  • 对于银屑病关节炎患者,托法替布可能比安慰剂更早实现疼痛改善。
  • 基线疼痛较高的患者接受托法替布可能疼痛改善更快。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. METHODS: Data from two trials (NCT01877668; NCT01882439) in patients receiving tofacitinib 5 mg twice daily, placebo switching to tofacitinib 5 mg twice daily at month 3 (placebo-to-tofacitinib) or adalimumab (NCT01877668 only) were included. Improvement in pain (≥30%/≥50% decrease from baseline in Visual Analogue Scale pain score) was assessed; median time to initial (first post-baseline visit)/continued (first two consecutive post-baseline visits) pain improvement was estimated (Kaplan-Meier) for all treatment arms. A parametric model was used to determine the relationship between baseline pain severity and time to pain response in patients receiving tofacitinib. RESULTS: At month 3, more patients experienced pain improvements with tofacitinib/adalimumab versus placebo. Median days (95% CI) to initial/continued pain improvements of ≥30% and ≥50%, respectively, were 55 (29-57)/60 (57-85) and 85 (57-92)/171 (90-not estimable (NE)) for tofacitinib, versus 106 (64-115)/126 (113-173) and 169 (120-189)/NE (247-NE) for placebo-to-tofacitinib. Pain improvements were also experienced more quickly for adalimumab versus placebo. Predicted time to ≥30%/≥50% pain improvement was shorter in patients with higher baseline pain versus lower baseline pain (tofacitinib arm only). CONCLUSIONS: In patients with PsA, pain improvements were experienced by more patients, and more rapidly, with tofacitinib and adalimumab versus placebo. In those receiving tofacitinib, higher baseline pain was associated with faster pain improvements.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. de Vlam K, Ogdie A, Bushmakin AG, et al. Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib. RMD Open. 2021. PMID: 34226183. doi:10.1136/rmdopen-2021-001609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。